Weir B, Band P, Urtasun R, Blain G, Mclean D, Wilson F, Mielke B, Grace M
J Neurosurg. 1976 Aug;45(2):129-34. doi: 10.3171/jns.1976.45.2.0129.
Forty-one consecutive patients with supratentorial primary brain tumors (38 Grade III and IV astrocytomas, one giant-cell astrocytoma, and two cases with insufficient tissue for diagnosis) were randomly allocated within 2 weeks of surgery to one of three therapeutic groups. Group 1 (15 patients) received radiation therapy totaling 4000 to 4500 rads in 4 to 5 weeks. Group 2 (13 patients) received 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea CCNU) 130 mg/sq m orally every 6 weeks. Group 3 (13 patients) received radiation therapy plus CCNU as for Groups 1 and 2. When the disease progressed, patients in Groups 1 and 2 were crossed over to receive CCNU and irradiation respectively. The median survival time in these groups was 188, 259, and 252 days, and the mean survival 263, 262, and 329 days. The median time from diagnosis to crossover (Groups 1 and 2) or to progression (Group 3) was 163, 99, and 220 days, and the mean time was 172, 108, and 231 days. There was no statistically significant difference between the means or medians in any of these situations.
41例连续性幕上原发性脑肿瘤患者（38例III级和IV级星形细胞瘤、1例巨细胞星形细胞瘤以及2例组织不足以诊断的病例）在术后2周内被随机分配至三个治疗组之一。第1组（15例患者）在4至5周内接受总量为4000至4500拉德的放射治疗。第2组（13例患者）每6周口服1-(2-氯乙基)-3-环己基-1-亚硝基脲（CCNU）130mg/m²。第3组（13例患者）接受与第1组和第2组相同的放射治疗加CCNU。当疾病进展时，第1组和第2组的患者分别交叉接受CCNU和放疗。这些组的中位生存时间分别为188、259和252天，平均生存时间分别为263、262和329天。从诊断到交叉（第1组和第2组）或进展（第3组）的中位时间分别为163、99和220天，平均时间分别为172、108和231天。在任何这些情况下，均值或中位数之间均无统计学显著差异。
